Analog Devices’ Data Acquisition IC Simplifies Industrial and Instrumentation Equipment Design
ADI’s ADAS3022 integrates a complete precision data acquisition analog signal chain in a single integrated circuit.
Analog Devices, Inc. (ADI), the global leader in data-conversion technology*, today introduced a highly integrated data acquisition IC (integrated circuit) that uses one-third the board space of competing discrete devices to help engineers simplify the design and reduce the size of advanced industrial data acquisition systems. The new 16-bit, 1-MSPS (million-samples-per-second) ADAS3022 data acquisition IC is effective for power-line monitors, process and motor control, patient monitoring, and other industrial and instrumentation systems that operate within the ±10-V industrial range.
- Download data sheet, view product page, and request samples: http://www.analog.com/ADAS3022
- Get support at ADI’s EngineerZone™ online technical support community: http://ez.analog.com/welcome
“With a dominant global data conversion market share of approximately 48.5 percent in 2011, Analog Devices is considered by Databeans as the guiding force in the cutting edge data acquisition and signal conditioning market. With unique new products such as the ADAS3022, which promises very high performance in a smaller form factor, Analog Devices remains responsible for many of the high-level advancements that drive this dynamic industry forward,” said Matthew Scherer, market analyst, Databeans Inc. “As a result of such product releases, Databeans believe that Analog Devices is well positioned to remain the dominant player in this market for years to come.”
The ADAS3022 data acquisition IC integrates ADI’s 16-bit PulSAR® successive-approximation A/D converter core with high-impedance input buffers and a 7-stage on-chip PGIA (programmable-gain instrumentation amplifier). The ADAS3022 includes an 8-channel, low-leakage multiplexer and precision low-drift 4.096-V reference. With eight data channels and delivering full 16-bit dynamic range, the new IC is optimized to interface with a wide range of sensors running from ±10 V to as low as ±640 mV.
The ADAS3022 offers a complete factory calibrated and tested signal chain. This addresses the settling time, signal buffering, level shifting, noise amplification/rejection and other analog signal-conditioning challenges that were once a standard part of the system design process.
Recommended Complementary Components
Complementary components for the ADAS3022 include the ADR381 band gap voltage reference , ADR434x XFET voltage reference , ADR454x ultra-low-noise voltage reference , ADP1613/14 step-up PWM switching converter , ADP1715 linear regulator , ADP3334 linear regulator , ADP7102/04 CMOS low-noise LDO , AD8031/32 low power reference buffer, and ADA4841 low power ADC drivers for auxiliary input pair (AUX±). An evaluation board is also available that allows system designers to configure the ADAS3022 without engaging in circuit-board design or writing software code.
Pricing and Availability
Product | Sampling | Temperature Range | Price Each Per 1,000 | Packaging | ||||||||||||
Now | –40°C to +85°C | $14.95 |
6 mm x 6 mm
40-lead LFCSP ((lead-frame chip-scale package) |
|||||||||||||
About Analog Devices
Innovation, performance, and excellence are the cultural pillars on which Analog Devices has built one of the longest standing, highest growth companies within the technology sector. Acknowledged industry-wide as the world leader in data conversion and signal conditioning technology, Analog Devices serves over 60,000 customers, representing virtually all types of electronic equipment. Analog Devices is headquartered in Norwood, Massachusetts, with design and manufacturing facilities throughout the world. Analog Devices is included in the S&P 500 Index.
* Analog Devices, Inc. leads the worldwide data converter market with a 48 percent share, according to industry analyst firm Databeans , Inc. in its market research report titled “2011 Data Converters.” Analog Devices’ share is larger than the combined market share of the nearest eight competitors.
Follow ADI on Twitter at http://www.twitter.com/ADI_News
Subscribe to Analog Dialogue , ADI’s monthly technical journal, at: http://www.analog.com/library/analogDialogue/
PulSAR is a registered trademark of Analog Devices, Inc.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50473242&lang=en
Contact:
Analog Devices, Inc.
Grainne Murphy, +353-61-495540
grainne.murphy@analog.com
or
Andrew
MacLellan
Porter Novelli, 617-897-8270
andrew.maclellan@porternovelli.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom